Annexon Inc.

3.91+0.0600+1.56%Vol 280.38K1Y Perf -83.92%
Jun 27th, 2022 16:00 DELAYED
BID3.90 ASK3.97
Open3.82 Previous Close3.85
Pre-Market- After-Market3.91
 - -  - -%
Target Price
22.20 
Analyst Rating
Strong Buy 1.00
Potential %
467.78 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
8.12 
Earnings Rating
Market Cap150.78M 
Earnings Date
15th Aug 2022
Alpha-0.06 Standard Deviation0.23
Beta0.74 

Today's Price Range

3.584.08

52W Range

2.0624.85

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
21.81%
1 Month
19.57%
3 Months
29.47%
6 Months
-67.52%
1 Year
-83.92%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANNX3.910.06001.56
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.00-0.928.00
Q04 2021-0.90-0.97-7.78
Q03 2021-0.88-0.93-5.68
Q02 2021-0.68-0.82-20.59
Q01 2021-0.60-0.68-13.33
Q04 2020-0.42-0.61-45.24
Q03 2020-0.34-0.77-126.47
Q02 2020-0.53-28.87-5 347.17
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date15th Aug 2022
Estimated EPS Next Report-0.94
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume280.38K
Shares Outstanding38.56K
Shares Float36.45M
Trades Count3.51K
Dollar Volume1.09M
Avg. Volume832.93K
Avg. Weekly Volume1.22M
Avg. Monthly Volume628.96K
Avg. Quarterly Volume649.71K

Annexon Inc. (NASDAQ: ANNX) stock closed at 3.85 per share at the end of the most recent trading day (a -1.53% change compared to the prior day closing price) with a volume of 3.65M shares and market capitalization of 150.78M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. Annexon Inc. CEO is Douglas Love.

The one-year performance of Annexon Inc. stock is -83.92%, while year-to-date (YTD) performance is -65.97%. ANNX stock has a five-year performance of %. Its 52-week range is between 2.06 and 24.85, which gives ANNX stock a 52-week price range ratio of 8.12%

Annexon Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -47.85%, a ROC of -47.40% and a ROE of -53.49%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Annexon Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.94 for the next earnings report. Annexon Inc.’s next earnings report date is 15th Aug 2022.

The consensus rating of Wall Street analysts for Annexon Inc. is Strong Buy (1), with a target price of $22.2, which is +467.78% compared to the current price. The earnings rating for Annexon Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Annexon Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Annexon Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.98, ATR14 : 0.31, CCI20 : 135.89, Chaikin Money Flow : -0.07, MACD : 0.11, Money Flow Index : 66.78, ROC : -5.17, RSI : 60.94, STOCH (14,3) : 74.58, STOCH RSI : 0.92, UO : 62.69, Williams %R : -25.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Annexon Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.

CEO: Douglas Love

Telephone: +1 650 822-5500

Address: 180 Kimball Way, South San Francisco 94080, CA, US

Number of employees: 38

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

72%28%

Bearish Bullish

67%33%

TipRanks News for ANNX

Tue, 10 May 2022 11:36 GMT Annexon Biosciences (ANNX) Receives a Buy from Needham

- TipRanks. All rights reserved.

News

Stocktwits